Stock report · Delisted · Nasdaq
Portage Biotech Inc (PRTG)
4.70USD Delisted Final close · Nov 5, 2025
PRTG no longer trades. Portage Biotech was delisted from the Nasdaq in November 2025.
All prices on this page are historical. The last trade was on November 5, 2025, at $4.70.
PRTG stock price history
Final trading statistics
- Final close
- $4.70
- Final trading day
- Nov 5, 2025
- Market cap at delisting
- $10.71M
- Shares outstanding
- 2.28M
- Final 52-week range
- $2.95 – $15.82
- Avg. volume (final 3 mo.)
- 823,644
- All-time high
- $136500.06 · Nov 1995
- All-time low
- $0.20 · Nov 2019
- Return since IPO
- -100.0%
- Beta
- 0.64
- Book value / share
- −$0.07
- Price / book
- -63.51
About Portage Biotech Inc
Portage Biotech Inc. was a clinical stage immune-oncology company researching drug and biotech products. PORT-3 was in phase 1 for NY-ESO-1 positive tumors, and PORT-6, a selective A2A receptor antagonist, was in phase 1a for solid tumors.
Preclinical work included PORT-8, which blocks both A2A and A2B adenosine receptors; PORT-9, an A2B antagonist aimed at colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulation; and PORT-5, a VLP-STING for solid tumors. PORT-7 was another selective A2B antagonist.
The company was based in Tortola, British Virgin Islands. Its shares were delisted from the Nasdaq in November 2025, with a final trade on November 5, 2025 at $4.70.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Tortola
- Employees
- 3
- IPO date
- February 25, 2021
- Delisted
- November 5, 2025
- SEC CIK
- 1095435
Portage Biotech financials before the delisting
The last 5 fiscal years Portage Biotech reported as a public company, fiscal year ending March.
PRTG revenue and net income
PRTG earnings per share
PRTG annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $0.00 | −$6.8M | — |
| FY2024 | $0.00 | −$75.3M | −$24.81 |
| FY2023 | $0.00 | −$104.6M | −$5.99 |
| FY2022 | $0.00 | −$16.9M | −$1.29 |
| FY2021 | $0.00 | −$15.8M | −$1.23 |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Portage Biotech stock FAQ
What happened to Portage Biotech stock?
Portage Biotech was delisted from the Nasdaq in November 2025. The final close was $4.70 on November 5, 2025.
Can I still buy PRTG stock?
No. PRTG is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on November 5, 2025.
What was the last price of PRTG?
PRTG last closed at $4.70 on November 5, 2025, which valued the company at about $10.71M.
How did Portage Biotech do in its last full fiscal year?
In fiscal 2025, its last full year as a public company, Portage Biotech reported revenue of $0.00 and net income of −$6.8M.
When did Portage Biotech go public?
Portage Biotech shares started trading on February 25, 2021.
PRTG no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.